Health care’s high rollers: As the pandemic raged, CEOs’ earnings surged
Health care’s top executives sat comfortably atop their perch during the second year of the…
Category: Business
STAT+: HCA, Steward abandon hospital deal in another win for FTC
For-profit hospital chains HCA Healthcare and Steward Health Care have terminated their proposed hospital sales,…
STAT+: Many Blue Cross Blue Shield plans aren’t paying taxes — and instead are swimming in refunds
The Blue Cross Blue Shield system of health insurance companies boasts on its website, “We…
STAT+: New Jersey hospitals scrap merger after FTC challenge
Two New Jersey hospital systems have called off their proposed merger less than two weeks…
STAT+: Real estate firms own nearly 1 in 10 health care properties
Not all hospitals and nursing homes own the property they sit on, and new research…
STAT+: Omicron squeezed hospitals more than health insurers in the first quarter
The beginning of 2022 was kinder to health insurers than it was to hospitals. Many…
STAT+: Despite biotech slump, veterans of SVB and KKR launch investment firm
Two of the top health care investors at the investment bank SVB Securities and the…
The doctor who is trying to bring back surprise billing
If Daniel Haller gets his way, surprise medical bills will be back in full force….
‘We are not casting a wide enough net’: Rob Perez on how biopharma companies can help out their neighbors
If it wasn’t for a well-placed ad in the paper, Rob Perez might not have…
STAT+: A hospital lobbying juggernaut makes an unlikely pivot into venture capital
The American Hospital Association is a lobbying powerhouse, championing the interests of its thousands of…
STAT+: TeamHealth hit with another lawsuit for alleged overbilling, this time from an employer
A Louisiana employer filed a class-action lawsuit against TeamHealth, alleging the private-equity-backed physician staffing firm…
STAT+: The biggest PBMs are handling more and more of the country’s drug price negotiations
Alex Schmelzer didn’t think he’d be the most-hated person in drug pricing negotiations, but he…
STAT+: Patients are flocking back to hospitals, but volumes are at the mercy of Covid surges, new documents show
Hospitals and outpatient clinics filled up with patients early last year, as vaccines and the…
‘It’s not medical’: Oregon wrestles with how to offer psychedelics outside the health care system
PORTLAND, Ore. — Visitors to the fabric store, kitty-corner to a Whole Foods, are greeted…
STAT+: A glaring gap in Congress’ surprise billing law leaves patients on the hook for pricey, out-of-network lab tests
For Soung Luy, it seemed easy: His primary care doctor told him he needed blood…
STAT+: Even as it struggles, startup insurer Bright Health deepens its ties to Cigna
Bright Health is hemorrhaging money, raising questions not only about its future but also about…
.jpg)
The Catholic hospital system Ascension is running a Wall Street-style private equity fund
WASHINGTON — America’s largest Catholic hospital system, Ascension, has quietly built out a strikingly unusual…
STAT+: How America’s largest Catholic hospital system is moonlighting as a private equity firm
The nation’s largest Catholic hospital system, a sprawling behemoth of more than 140 hospitals called…
Latest psilocybin patent highlights the swirling battle over psychedelics intellectual property
One of the leading companies racing to develop psychedelics as legal medicines was granted a…
STAT+: In a sea of skeptics, this physician was one of fibromyalgia patients’ few true allies. Or was he?
Cindy Bradley-Graziadei almost didn’t take the test. By the time she saw it advertised, in…
Lawyers for Henrietta Lacks estate say more companies to be sued over use of her cells
Trillions of her cells have played a pivotal role in medical research for the past…
Third member of FDA expert committee resigns over controversial Alzheimer’s therapy decision
A third member of a Food and Drug Administration expert panel has resigned over the…
Member of FDA’s expert panel resigns over controversial Alzheimer’s therapy approval
Following the Food and Drug Administration’s polarizing authorization of the Alzheimer’s therapy Aduhelm on Monday,…
STAT+: Martin Shkreli’s longtime friend wants to undo his 4,000% price hike. But first he’ll have to finally oust the ‘pharma bro’
Martin Shkreli’s drug company has a lot of problems. Revenue was cut in half last…
Medical device firms’ payments to doctors far outstripped those from pharma, study shows
WASHINGTON — The medical device industry gave doctors consulting fees, lunches, lodging, and other incentive…
STAT+: Boston’s hospital chiefs moonlight on corporate boards at rates far beyond the national level
As chief of Boston Children’s Hospital, one of the most esteemed pediatric hospitals in the…
STAT+: Behind the scenes, companies helping big Covid-19 vaccine makers are getting rich
Pfizer and Moderna aren’t the only vaccine money-makers. Much of the revenue and profits from…
STAT+: OpenBiome to wind down stool bank operations
OpenBiome, the nation’s first public stool bank, will soon end its program for collecting, screening,…
As health tech flourished, Teladoc and Livongo saw an opportunity to ‘accelerate,’ executives say
It took a lot of late-night and early-morning Zoom calls plus some socially distanced in-person…
STAT Plus: Foundation Medicine wins FDA approval for first liquid biopsy able to detect multiple cancers
The Food and Drug Administration on Wednesday approved the first comprehensive “liquid biopsy” platform that…
The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review
The Food and Drug Administration has agreed to review a marketing application submitted by Biogen…
STAT Plus: Coles-led Cerevel Therapeutics to raise $445 million to develop brain drugs with fewer side effects
Cerevel Therapeutics, a Boston neuroscience company spun out from Pfizer in 2018 and led by…
STAT Plus: The biotech scorecard for the third quarter: 14 stock-moving events to watch
Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT Plus: FDA rejects Intercept Pharma’s drug for NASH
Intercept Pharmaceuticals said Monday that the Food and Drug Administration rejected its drug to treat…
STAT Plus: Zogenix wins approval for new drug to treat rare type of childhood epilepsy
A new drug from Zogenix that treats a rare and severe type of epilepsy was…
STAT Plus: After a bribery scandal in China, GSK found a suspected whistleblower. The real one is still waiting in the shadows
Alarmed that colleagues were bribing Chinese doctors and giving kickbacks to hospital workers to boost…
STAT Plus: A crucial study of Bellus Health’s chronic cough drug reads out soon. Here’s what you need to know
Bellus Health, a small Canadian drug maker, is seeking to develop a potential blockbuster medicine…
STAT Plus: A ‘semi-wartime’ effort: Thermo Fisher COO on adapting the business to a Covid-19 world
Way back in January, Thermo Fisher Scientific (TMO), the world’s largest maker of scientific tools,…
STAT Plus: Court invalidates Biogen’s patent on blockbuster multiple sclerosis drug
Shares of Biogen fell Thursday after a federal court judge ruled in favor of generic…
STAT Plus: Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it
Q32 Bio has two targets in its sights: the two arms of the immune system….
STAT Plus: ‘One thing cancer patients don’t generally have is time’: New cancer research leader brings urgency to Sanofi
Peter Adamson joined Sanofi in late March, as the coronavirus pandemic surged around the world…
STAT Plus: Startup Spotlight: Aiming to speed precision cancer therapies to children
For some children with a certain type of brain tumor, treatment can mean surgery followed…
STAT Plus: Two years of halting progress and high turnover preceded Atul Gawande’s exit as Haven CEO
Atul Gawande’s announcement last week that he was stepping down as CEO of a high-profile…
Gawande says leaving Haven CEO job will allow him to focus on Covid-19
Atul Gawande on Wednesday confirmed that he will step down as chief executive of the…
STAT Plus: Atul Gawande to depart as CEO of splashy health venture. Is it ‘a death knell’?
It seemed an ideal partnership: Three of America’s most powerful companies were teaming up with…
STAT Plus: With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake
Never in modern times have such high hopes for millions of lives rested on one…
Gilead’s remdesivir has seen success against the coronavirus. Now the company has to make enough to supply the world
In January, Gilead Sciences wasn’t manufacturing more than a few doses of its experimental antiviral…
STAT Plus: Patients, drug makers grapple with how to continue cancer trials during the coronavirus
The coronavirus pandemic has thrown a wrench into plans for hundreds of clinical trials seeking…
STAT Plus: Biogen delays Alzheimer’s drug filing to FDA, citing Covid-19, complexity of data analysis
Biogen said Wednesday that the submission of a U.S. marketing application for its Alzheimer’s drug…
Video Chat: Combating Covid-19
The pandemic caused by the novel coronavirus has shut down countries around the world. One…